Regenxbio Valuation Multiples

Regenxbio Overview

About Regenxbio

Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.

Founded

2008

HQ

Employees

353

Website

regenxbio.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $188M

EBITDA: ($137M)

EV

$270M

Valuation Multiples

Multiples.vc

Start free trial

Regenxbio Financials

Regenxbio reported last 12-month revenue of $188M and negative EBITDA of ($137M).

In the same LTM period, Regenxbio generated $168M in gross profit, ($137M) in EBITDA losses, and had net loss of ($185M).

Regenxbio P&L

In the most recent fiscal year, Regenxbio reported revenue of $170M and EBITDA of ($133M).

Regenxbio expects next 12-month revenue of XXX and NTM EBITDA of XXX

Regenxbio Stock Performance

Regenxbio has current market cap of $468M, and enterprise value of $270M.

Regenxbio's stock price is $9.24.

Regenxbio Valuation Multiples

Regenxbio trades at 1.4x EV/Revenue multiple, and (2.0x) EV/EBITDA.

Regenxbio Financial Valuation Multiples

As of March 21, 2026, Regenxbio has market cap of $468M and EV of $270M.

Equity research analysts estimate Regenxbio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Regenxbio has a P/E ratio of (2.5x).

Regenxbio Margins & Growth Rates

Regenxbio's revenue in the last 12 month grew by 39%.

Regenxbio's revenue per employee in the last FY averaged $0.5M.

Regenxbio's rule of 40 is (34%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Regenxbio's rule of X is 25% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Regenxbio Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Regenxbio M&A Activity

Regenxbio acquired XXX companies to date.

Last acquisition by Regenxbio was on XXXXXXXX, XXXXX. Regenxbio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Regenxbio Investment Activity

Regenxbio invested in XXX companies to date.

Regenxbio made its latest investment on XXXXXXXX, XXXXX. Regenxbio invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).